Related Experiment Video

Updated: Jan 22, 2026

Quantification of Global Diastolic Function by Kinematic Modeling-based Analysis of Transmitral Flow via the Parametrized Diastolic Filling Formalism
11:04

Quantification of Global Diastolic Function by Kinematic Modeling-based Analysis of Transmitral Flow via the Parametrized Diastolic Filling Formalism

Published on: September 1, 2014

11.6K

Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients

Munemitsu Otagaki1, Koichiro Matsumura2, Hiromi Kin1

  • 1Department of Cardiology, Kansai Medical University Medical Center, 10-15, Fumizono-cho, Moriguchi, Osaka, 570-8507, Japan.

Cardiovascular Drugs and Therapy
|July 20, 2019
PubMed
Abstract

Insights

Tofogliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, improved cardiac function in type 2 diabetes mellitus (T2DM) patients. This SGLT2 inhibitor enhanced both systolic and diastolic left ventricular function, suggesting a potential cardiovascular benefit.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Sodium glucose cotransporter 2 (SGLT2) inhibitors demonstrate cardiovascular benefits in diabetic patients.
  • The precise mechanisms underlying these cardiovascular improvements remain under investigation.
  • Type 2 diabetes mellitus (T2DM) is associated with increased cardiovascular risk and impaired cardiac function.

Purpose of the Study:

  • To evaluate the impact of tofogliflozin, an SGLT2 inhibitor, on cardiac function in patients with T2DM.
  • To assess changes in left ventricular systolic and diastolic function following tofogliflozin administration.

Main Methods:

  • A prospective study involving T2DM outpatients initiating tofogliflozin.
  • Echocardiography was performed before and at least 6 months after tofogliflozin initiation.
  • A propensity score-matched control group of T2DM patients on other glucose-lowering drugs was included for comparison.
  • Left ventricular ejection fraction (LVEF) assessed systolic function; early diastolic velocity (E/e') assessed diastolic function.

Main Results:

  • No significant baseline differences in patient characteristics or echocardiographic parameters between groups.
  • The tofogliflozin group showed a significant improvement in LVEF (5.0 ± 6.9%) compared to the control group (-0.6 ± 5.5%; p=0.006).
  • Diastolic function, measured by E/e', significantly improved in the tofogliflozin group (-1.7 ± 3.4) compared to the control group (0.7 ± 4.1; p=0.024).

Conclusions:

  • Tofogliflozin administration, in addition to conventional therapies, positively impacts left ventricular systolic function in T2DM patients.
  • Tofogliflozin also demonstrates a beneficial effect on left ventricular diastolic function in patients with T2DM.
  • These findings suggest SGLT2 inhibition may offer direct cardiac benefits beyond glycemic control in T2DM.
Keywords:
Cardiac functionDiabetes mellitusSGLT2 inhibitorTofogliflozin

More Related Videos

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice03:17

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice

Published on: March 29, 2024

979
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.3K

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.4K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.0K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.2K
Cell Adhesion Molecules - Types and Functions01:20

Cell Adhesion Molecules - Types and Functions

Cell adhesion molecules (CAMs) are pivotal to multicellularity and the coordinated functioning of tissues and organ systems. They enable physical interactions between cells and provide mechanical strength to tissues. They also function as receptors for signal transmission across the plasma membrane. The CAMs are broadly classified into four families - integrins, cadherins, selectins, and immunoglobulin-like CAMs (IgCAMs).
CAM Families
The Integrin family of proteins is primarily  involved...
9.1K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.2K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
875